The UK-based Dementia Discovery Fund is investing $1.3M in Immuneering's drug-discovery technology in search of new molecular entities for treating Alzheimer's.
An association study involving more than 100,000 individuals led to overlapping and distinct variants involved in bipolar disorder, schizophrenia, and subtypes of each.
The multi-year renewal includes DNA Genotek's Oragene-Dx saliva kits and GenoFIND services for custom collection kit packaging and order fulfillment services.
By combining iPSCs, CRISPR gene editing, and transcriptomic approaches, researchers examined the effects of an Alzheimer's disease risk variant on brain cells.
